Proteomics Laboratory
To improve our understanding of the proteins that are relevant to the cancer process, Cancer Biomarker and Proteomics Laboratory was established at Shiraz Institute for Cancer Research (ICR) in June 2007. Proteomics is the simultaneous study of the nearly all the proteins in a cell type or tissue, and the changes during various conditions. In contrary to the genome which is constant in almost all the cells of an individual, the proteome differs from cell to cell and is constantly changing through biochemical interactions with the genome and the environment.
Since proteins play a central role in the life of an organism, proteomics is instrumental in discovery of differentially expressed proteins and biomarkers; the gold molecules in diagnosis, drug discovery, vaccine development and screening. The identification of potential new drugs and vaccines for the treatment of, and preventing the diseases are new promising developments to come from proteomics studies. In the past decade, proteomics has been extensively used to identify tumor-associated antigens, immunogens capable of inducing autoantibodies, in patients with cancer. In this regard, immunoproteomics has been developed to identify tumor-associated antigens (TAAs). The new candidate markers that are discovered and introduced with high-throughput proteomics require extensive verification and validation with several approaches such as ELISA, Western blot and IHC. The main goals of the projects at Cancer Biomarker and Proteomics Laboratory are discovery, verification and validation of differentially expressed proteins in patients' samples as well as identification of tumor antigens that react with sera's autoantibodies. Another goal of the Cancer Biomarker and Proteomics Laboratory is to investigate molecular (mostly proteins) and cellular changes in response to anticancer drugs in mouse models of breast cancer and colon cancer (tumor is induced through cell line injection at our own laboratory). Previous published works have identified and characterized some differentially expressed proteins and some antibody reactive proteins in tissue, serum and mesenchymal stem cells (MSCs) isolated from tumor tissue in different types of cancers including salivary gland tumors, pancreatic cancer and breast cancer. An international collaboration to catalog all human proteins and ascertain their functions and interactions is being co-coordinated by the Human Proteome Organization (HUPO, http://www.hupo.org/ ).
Cancer Biomarker and Proteomics Laboratory at Shiraz Institute for Cancer Research is a collaborative center for protein and biomarker studies in the institute/university. Researchers at the laboratory are conducted by a team of researchers including Prof. Abbas Ghaderi and Mohammad Reza Haghshenas, PhD.
Articles
1-Saffarian A, Tarokh A, Haghshenas MR, Taghipour M, Chenari N, Ghaderi A, et al. Proteomics Study of Mesenchymal Stem Cell-Like Cells Isolated from Cerebrospinal Fluid of Patients with Meningioma. Current Proteomics. 2019; 16(4):282-8.
2-Rezaei M, Nikeghbalian S, Mojtahedi Z, Ghaderi A. Identification of antibody reactive proteins in pancreatic cancer using 2D immunoblotting and mass spectrometry. Oncology reports. 2018; 39(5):2413-2421.
3-Rostamzadeh D, Haghshenas MR, Daryanoosh F, Samadi M, Hosseini A, Ghaderi A, et al. Altered frequency of CD8(+) CD11c(+) T cells and expression of immunosuppressive molecules in lymphoid organs of mouse model of colorectal cancer. Journal of cellular physiology. 2019; 234(7):11986-98.
4-Rostamzadeh D, Yousefi M, Haghshenas MR, Ahmadi M, Dolati S, Babaloo Z. mTOR Signaling pathway as a master regulator of memory CD8(+) T-cells, Th17, and NK cells development and their functional properties. Journal of cellular physiology. 2019; 234(8):12353-68.
